HC Wainwright Expects Higher Earnings for Verve Therapeutics

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Verve Therapeutics in a research note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.16) per share for the year, up from their prior estimate of ($2.38). HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics' Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

A number of other research firms have also weighed in on VERV. Wall Street Zen raised Verve Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Canaccord Genuity Group boosted their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Guggenheim upped their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Royal Bank of Canada lowered their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $25.75.

Verve Therapeutics Stock Down 0.5%

Shares of NASDAQ:VERV traded down $0.02 during midday trading on Wednesday, reaching $4.36. The company's stock had a trading volume of 1,383,381 shares, compared to its average volume of 1,863,624. Verve Therapeutics has a 12-month low of $2.86 and a 12-month high of $9.31. The firm has a market capitalization of $388.66 million, a P/E ratio of -1.77 and a beta of 1.82. The firm has a 50 day moving average of $4.61 and a 200-day moving average of $5.80.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.

Hedge Funds Weigh In On Verve Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VERV. KFG Wealth Management LLC acquired a new stake in Verve Therapeutics during the 1st quarter worth about $46,000. IFP Advisors Inc boosted its stake in shares of Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after buying an additional 8,237 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in Verve Therapeutics during the first quarter worth about $47,000. E Fund Management Co. Ltd. purchased a new position in Verve Therapeutics during the first quarter valued at approximately $48,000. Finally, BNP Paribas Financial Markets purchased a new position in Verve Therapeutics during the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.